Top news June 2023: FDA approvals, updates from NLA and more

Healio | Cardiology Today has compiled a list of the top headlines in cardiology of June 2023.

Readers were most interested in the FDA approvals of colchicine 0.5 mg, IV ferric carboxymaltose and mavacamten for various CV indications; updates from the National Lipid Association Scientific Sessions and Heart in Diabetes CME Conference; and more.

FDA approves CV version of colchicine for patients with residual inflammatory risk

Agepha Pharma announced that the FDA approved a 0.5 mg dose of colchicine for reduction of CV events in patients with atherosclerotic CVD or multiple CV risk factors who have residual inflammatory risk. Read more

AI models identify five distinct heart failure types, better predicting prognosis

Researchers have identified five distinct heart failure subtypes using machine learning methods across nationally representative datasets that may predict prognosis and ultimately guide treatment plans for patients. Read more

FDA approves first IV iron replacement therapy for heart failure

The FDA approved the first IV ferric carboxymaltose injection for iron deficiency in adults with HF to improve exercise capacity, according to a press release from American Regent. Read more

Alcohol intake may lower stress-related brain activity, helping the heart

Compared with no or little alcohol intake, consuming one to 14 drinks per week is associated with lower risk for major adverse CV events, likely due to an alcohol-mediated reduction in stress-associated brain activity, researchers reported. Read more

Coronary CT may be best diagnostic strategy when evaluating stable chest pain

For adults with stable chest pain, coronary CTA may be as useful as direct invasive coronary angiography and may be the best diagnostic strategy vs. stress testing and single-photon emission CT myocardial perfusion imaging, data show. Read more

ROSE2: Obicetrapib/ezetimibe combination further lowers LDL in statin-treated patients

In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial. Read more

‘Unlearn concern’ about going too low with LDL

LDL is a central component of CV risk reduction and data now show clear benefits of a sustained and substantial reduction, even in the setting of very high baseline LDL, according to a speaker. Read more

Meta-analysis confirms benefits of SGLT2 inhibitors in various high-risk populations

SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology. Read more

Dietary sources, not supplements, ideal for calcium, vitamin D

Multiple studies report associations between low blood vitamin D level and worse CV health, but supplements are likely not the answer for many patients. Read more

FDA approves updated label for mavacamten

Bristol Myers Squibb announced that the FDA has approved updated labeling for mavacamten to reflect positive data from the VALOR-HCM trial. Read more